Viking Therapeutics Inc. (NASDAQ: VKTX) announced it has completed patient enrollment in its Phase 3 VANQUISH-2 clinical trial evaluating VK2735 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE